Document Detail


Beneficial effects of statin therapy on survival in hypertensive patients with acute myocardial infarction: data from the RICO survey.
MedLine Citation:
PMID:  17954357     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Randomized studies have shown a reduction in cardiovascular events associated with low doses of statin among hypertensive patients at only moderate cardiovascular risk. The hypothesis of the present study was that statin therapy initiated during hospitalization could improve the long-term outcome after acute myocardial infarction (MI) in hypertensive patients. METHODS: From the French regional obserRvatoire des Infarctus de Côte d'Or (RICO) survey, 1076 patients with a history of hypertension, surviving acute MI were included. Patients on statin therapy initiated before their hospitalization were excluded from the study. Patients were categorized into two groups based on whether or not statin treatment was initiated during the hospital stay. RESULTS: Patients in the statin group were younger (70 years [range, 58 to 77 years] v 75 years [range, 65 to 82 years], P < .001) and were more likely to have hypercholesterolemia (42% v 28 %, P < .001). No differences were observed between the two groups for LDL-cholesterol levels on admission. At 1-year follow-up, cardiovascular mortality and rehospitalization for heart failure were lower in the statin group (respectively, 5% v 15%, P < .001; 5% v 7%, P < .001). Multivariate analysis showed that statin therapy was associated with decreased mortality (hazard ratio [95% confidence interval; CI]: 0.58 [0.32-0.98], P = .035) independently of either hypercholesterolemia, the use of beta-blockers, angiotensin-converting enzyme inhibitors, or diuretics, but not with a decreased incidence of heart failure (hazard ratio [95% CI]: 0.88 [0.55-1.23], P = .152). CONCLUSIONS: In this observational study, the long-term benefits of statin therapy initiated in-hospital in hypertensive patients after acute MI was demonstrated. These findings may have implications for treatment optimization of hypertensive patients in secondary prevention.
Authors:
Pierre Sicard; Marianne Zeller; Gilles Dentan; Yves Laurent; Claude Touzery; Isabelle L'huillier; Luc Janin-Manificat; Luc Lorgis; Jean-Claude Beer; Hamib Makki; Luc Rochette; Yves Cottin;
Related Documents :
1936477 - Comparative efficacy of metformin and glibenclamide in patients with non-insulin-depend...
20151997 - Ezetimibe added to atorvastatin compared with doubling the atorvastatin dose in patient...
15186887 - Are unnecessary follow-up procedures induced by computer-aided diagnosis (cad) in mammo...
11588947 - Comparison of effects of continuous combined transdermal with oral estrogen and oral pr...
12677757 - Endovascular brachytherapy in peripheral arteries.
9839147 - Serum time course of naltrexone and 6 beta-naltrexol levels during long-term treatment ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of hypertension     Volume:  20     ISSN:  0895-7061     ISO Abbreviation:  Am. J. Hypertens.     Publication Date:  2007 Nov 
Date Detail:
Created Date:  2007-10-23     Completed Date:  2008-01-23     Revised Date:  2009-02-24    
Medline Journal Info:
Nlm Unique ID:  8803676     Medline TA:  Am J Hypertens     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1133-9     Citation Subset:  IM    
Affiliation:
Laboratoire de Physiopathologie et Pharmacologie Cardio-vasculaires Expérimentales, IFR Santé-STIC, Facultés de Médecine et de Pharmacie, Dijon, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Aged
Aged, 80 and over
C-Reactive Protein / metabolism
Data Collection
Databases, Factual
Female
France / epidemiology
Hospitalization
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
Hypertension / complications*
Lipids / blood
Logistic Models
Male
Middle Aged
Myocardial Infarction / complications,  mortality*
Odds Ratio
Recurrence / prevention & control
Risk Factors
Treatment Outcome
Chemical
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 0/Lipids; 9007-41-4/C-Reactive Protein

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  A device for testing the intrinsic muscles of the hand.
Next Document:  Relative impact of socioeconomic status on blood pressure lessons from a large-scale survey of young...